← All drugs built on NIH-funded research

Polarean · Xenon Xe-129 Hyperpolarized

Xenoview: patented from NIH-funded research

Duke University reported 2 patents on this drug to NIH as inventions made with NIH grant money. Polarean lists them with the FDA as protecting Xenoview.
Patent reported to NIH as grant-funded

Medicare paid, 2024

—

before rebates

Medicare, 2020–2024

$0

Medicaid paid, 2024

—

before rebates

NIH grants behind the patents

$14M

whole-grant totals, not the drug's cost

The public record, link by link

  1. 1 · Public money

    2 NIH grants to Duke University, $14M in all.

  2. 2 · Patent

    10583205, 11052161, reported to NIH under P41EB015897, R01HL105643.

  3. 3 · FDA approval

    Approved Dec 23, 2022, held by Polarean (NDA 214375).

  4. 4 · Public pays

    Not yet in the Medicare or Medicaid spending files, which run to 2024.

The grants

Totals are everything NIH paid on each grant since 1985. A grant usually funded more than this one invention.
GrantResearchYearsNIH paid
P41EB015897

NIBIB

INTEGRATED CENTER FOR IN VIVO MICROSCOPY

Duke University

2012–2017$7.4M
R01HL105643

NHLBI

Early Detection of Changes in Pulmonary Gas Exchange by Hyperpolarized Xe MRI

Duke University

2011–2026$6.7M

The patents

Patents the FDA lists for this drug that were also reported to NIH as grant-funded inventions.
  • US 10583205

    HYPERPOLARIZED NOBLE GAS PRODUCTION SYSTEMS WITH NANOCLUSTER SUPPRESSION, DETECTION AND/OR FILTERING AND RELATED METHODS AND DEVICES

    Reported by Duke University

    FDA-listed expiry Feb 20, 2035
  • US 11052161

    HYPERPOLARIZED NOBLE GAS PRODUCTION SYSTEMS WITH NANOCLUSTER SUPPRESSION, DETECTION AND/OR FILTERING AND RELATED METHODS AND DEVICES

    Reported by Duke University

    FDA-listed expiry Dec 29, 2035

Polarean's side

Drug makers pay for the clinical trials that take a compound from the lab to FDA approval, and they often license the patent from the university and pay royalties on sales. Those terms are not public. The FDA's approval records for Xenoview are linked above, and Polarean's page shows its other drugs on this list. If Polarean wants to add its account, we will publish it here.

How this is built. Universities and companies that use NIH grants must report the inventions those grants produce to NIH, under the Bayh-Dole Act. NIH publishes the patent numbers and the grants they were reported under. We match those patents to the patents drug makers list with the FDA for each approved drug (the Orange Book), then add what Medicare Part D, Part B and Medicaid paid for each drug. Only patents still listed with the FDA appear, so drugs whose patents have expired drop out, and biologics, which the Orange Book does not cover, are not here yet.

What the numbers mean. "NIH grants" is everything NIH paid out on the grants a patent was reported under, from 1985 on. A grant usually paid for more than the one invention, so it is not the cost of the drug. Medicare and Medicaid figures are gross spending before the rebates drug makers pay back, which are confidential. Companies also paid for the clinical trials that took these drugs to approval; each drug page links the company's own filings.

Sources: NIH RePORTER patents reported under NIH grants (from iEdison); NIH RePORTER project funding; FDA Orange Book patent and product files; Medicare Part D Spending by Drug; Medicare Part B Spending by Drug; Medicaid Spending by Drug. Updated 2026-11-05.